Tag: Dr. Andy Morgenstern

GLP-1 receptor agonists are gaining attention for a possible connection to vision loss and visual changes as their use rapidly increases in the United States. Medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are now used by nearly 6% of U.S. adults for diabetes and weight management, making regular eye exams and monitoring for vision changes increasingly important for patients taking GLP-1 medications.